TScan Therapeutics, Inc.TScan Therapeutics, Inc.TScan Therapeutics, Inc.

TScan Therapeutics, Inc.

No trades
See on Supercharts

TCRX fundamentals

Key facts

Market capitalization
Founded
CEO
Website
About

TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends
TCRX has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company